AI Reads Biopsy Slides to Predict Stomach Cancer Spread Before Surgery

For patients diagnosed with early gastric cancer, one of the most consequential questions in their care is deceptively simple: has the tumor already reached the lymph nodes? When cancer remains confined to the stomach lining and no lymph node metastasis is present, many patients can be cured with a local resection, sparing them a full gastrectomy with extensive lymph node dissection. But when the nodes are involved, that less invasive strategy is no longer adequate. A new study published in the Journal of Translational Medicine describes a deep learning system, called LMRNet, that attempts to answer this question before surgery by reading routine biopsy slides, and, unusually for an artificial intelligence model, explains which pathological features drive its predictions.

The research, led by Qi Lin and colleagues at the First Affiliated Hospital of Sun Yat-sen University together with collaborators across several Chinese institutions, enrolled a total of 660 patients with T1-stage gastric cancer whose lymph node status had been definitively confirmed after D2 lymphadenectomy, the standardized radical lymph node dissection used in surgical treatment. This design matters because it means the model was trained and evaluated against a ground truth established by actual surgical pathology rather than by inference. The team used hematoxylin and eosin stained biopsy slides, the most common and inexpensive preparation in pathology laboratories worldwide, as the sole input for their models.

Technically, the researchers did not rely on a single neural network architecture. Instead, they trained and compared multiple state-of-the-art vision models and found three that performed particularly well: ViTamin, a vision transformer variant; ConvNeXt V2, a modernized convolutional network; and Swin Transformer V2, a hierarchical transformer that processes images in shifted windows. These three were integrated into an ensemble, LMRNet, whose predictions combine the strengths of fundamentally different computational approaches to image recognition. Ensembling is a well-established strategy for improving robustness, because errors made by one architecture for one reason are often not shared by the others, and averaging their outputs tends to cancel out idiosyncratic mistakes while preserving genuine signal.

The performance figures are striking. In the internal biopsy cohort, LMRNet achieved an area under the receiver operating characteristic curve, or AUC, of 0.947, a level of discrimination that approaches the practical ceiling for a clinical prediction task. More importantly, in an external biopsy cohort drawn from patients the model had never seen, the AUC remained high at 0.900, suggesting the system generalizes across centers rather than memorizing site-specific artifacts such as staining protocols or scanner characteristics. When the team evaluated the model on multicenter surgical cohorts, performance remained stable with AUCs ranging from 0.768 to 0.894. The modest drop from biopsy to surgical specimens is expected, since the model was designed for the preoperative setting, but the stability across institutions is what separates a laboratory curiosity from a potentially deployable clinical tool.

What elevates this work beyond a standard prediction exercise is its second act: an effort to open the black box. The researchers deployed a dual Swin Transformer classifier to characterize histopathological subtypes within the slides and used HoVer-Net, a well-known algorithm for detecting and segmenting individual cell nuclei, to map the tumor microenvironment at cellular resolution. The subtype classifier showed strong agreement with annotations from The Cancer Genome Atlas, an independent reference standard, which lends credibility to its assignments. The analysis revealed that diffuse-type tumor regions, the histological pattern in which cancer cells infiltrate singly or in small clusters rather than forming cohesive glands, were associated with a higher predicted risk of lymph node metastasis. This aligns with decades of clinical observation that diffuse-type gastric cancers behave more aggressively.

The microenvironmental findings are arguably the most intriguing part of the study. When the team examined which image patches the model weighted most heavily, they found that regions enriched with inflammatory cells received significantly higher metastatic risk scores, particularly when those inflammatory cells sat in close spatial proximity to tumor cells. In other words, the model had learned, without ever being told, that the intimate juxtaposition of immune cells and malignant cells is a hallmark of tumors that spread. Conversely, regions in which stromal cells formed structural barriers separating tumor cells from inflammatory cells were assigned lower risk. The model appears to have captured a spatial grammar of tumor-host interaction: not merely which cells are present, but how they are arranged relative to one another.

These computational observations resonate with biological concepts that pathologists have long discussed qualitatively. Tumor-stroma interactions, immune infiltration, and the architectural patterns of invasion are all recognized determinants of metastatic behavior in gastrointestinal cancers. What LMRNet demonstrates is that a convolutional and transformer-based pipeline can extract these relationships quantitatively from a stained glass slide and convert them into a calibrated probability. The interpretability layer transforms the model from an oracle that simply outputs a number into an instrument that pathologists can inspect, question, and potentially trust, because its reasoning can be traced back to recognizable histological phenomena.

The clinical implications are considerable. Current preoperative assessment of lymph node involvement in early gastric cancer relies on endoscopic ultrasound and cross-sectional imaging, both of which have limited sensitivity for small volume nodal disease. Understaging can lead to inadequate treatment, while overstaging can push patients toward more radical surgery than they need. A tool that reads a standard biopsy slide, requires no additional tissue, no special stains, and no new procedures, and delivers a risk estimate with an AUC above 0.9 internally could meaningfully refine treatment planning. Patients flagged as low risk might be candidates for local resection, while those flagged as high risk could be directed toward more extensive surgery or neoadjuvant strategies, pending prospective validation.

Caveats remain. The study is retrospective, and the requirement for informed consent was waived on that basis, meaning the model has not yet been tested in a real-time clinical workflow where slide quality, biopsy sampling error, and case mix may differ from curated research cohorts. The performance range in surgical cohorts, while stable, also reminds us that the model’s confidence is calibrated to the preoperative specimen it was built for. The work was supported by the National Natural Science Foundation of China, the Natural Science Foundation of Guangdong Province, and a hospital research grant, and the authors declare no competing interests. Prospective, multi-center validation and integration into endoscopy and pathology information systems will be the necessary next steps.

Even so, the study offers a compelling glimpse of where digital pathology is heading. Rather than replacing pathologists, models like LMRNet may function as quantitative second readers, surfacing spatial and microenvironmental patterns that correlate with outcomes but are difficult to grade consistently by eye. The fact that an ensemble of three modern vision architectures, trained on nothing more exotic than routine H&E biopsies, can predict lymph node metastasis in early gastric cancer while pointing to biologically coherent features such as diffuse-type morphology and tumor-adjacent inflammation suggests that the morphological roots of metastasis are legible in the tissue itself. The task now is to prove, in the clinic, that this legibility translates into better decisions and better outcomes for patients facing one of the world’s most common cancers.

Subject of Research: Deep learning prediction of lymph node metastasis in early gastric cancer from biopsy histopathology

Article Title: LMRNet: a biopsy-derived deep learning model for predicting lymph node metastasis in early gastric cancer with pathological interpretability

Article References: Lin, Q., Liu, Y., He, J., Ruan, R., Guan, T., Zhang, Z., Chen, W., Luo, T., Tang, W., Wang, Z., He, Y., & Li, G. (2026). LMRNet: a biopsy-derived deep learning model for predicting lymph node metastasis in early gastric cancer with pathological interpretability. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08966-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08966-6

Keywords: early gastric cancer, lymph node metastasis, deep learning, digital pathology, biopsy, tumor microenvironment, Swin Transformer, ensemble model, histopathological subtype, predictive medicine, machine learning, cancer staging